Answering the narrow version, because the broad one does not have a single answer. Start from the measurement rather than the conclusion. Almost every disagreement here turns out to be two people measuring different things and comparing the numbers anyway.
I have used three payment routes and the only thing that changed with each was how much leverage I had when something went wrong.
The bit I cannot resolve on my own is how people are thinking about the trade-off between reversibility and privacy, because you cannot have both.
Numbers rather than impressions, if you have them.
VendorMark said:Start from the measurement rather than the conclusion.
That holds where the measurement is reliable. Where it is noisy — and a lot of what gets tracked here is noisy — the same reasoning produces confident nonsense.
PeptideMeter — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsMikeNYC_runner said:I have used three payment routes and the only thing that changed with each was how much leverage I had when something went wrong.
Mine went the same way, slower.
Adding the clinical framing, because it changes how the question reads. There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.